Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Success Rate

100.0%

+13.4% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 2
2(100.0%)
2Total
Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT04563871Phase 2Completed

Efficacy and Safety of 80mg Osimertinib in Patients With Non-small Cell Lung Cancer(NSCLC)

Role: lead

NCT05463224Phase 2Active Not Recruiting

Lazertinib for NSCLC Harboring Activating EGFR Mutations in TKI naïve Patients

Role: lead

NCT05937477Recruiting

Developing Artificial Intelligence-based Algorism to Predict Side Effects and Symptoms From Chemotherapy

Role: lead

All 3 trials loaded